



MAR 20 2003

**PATENT** 

**TECH CENTER 1600/2900** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Teng et al.

Application No.: 09/483,504

Group Art Unit: 1624

Filed: January 14, 2000

Examiner: To be assigned

Confirmation No. 8481

For: Non-Peptide GLP-1 Agonists

## RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, DC 20231

Sir:

This paper is being filed in response to the Office Action mailed February 11, 2003 that made restriction and election of species requirements. Applicants were requested to elect one of three designated groups, I -III, and a species within the elected group, for continued prosecution.

In response to these requirements, Applicants hereby elect the invention of Group III,

The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: March 11, 2003

Richard W. Bork, Reg. No. 36,459 Novo Nordisk Pharmaceuticals, Inc.

100 College Road West Princeton, NJ 08540 (609) 987-5800







MAR 20 2003

Attorney Docket No.: 5686.200-US

**PATENT** 

-- CMITER 1600/2900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Teng et al.

Serial No.: 09/483,504

Group Art Unit: 1614

Filed: January 14, 2000

Examiner: To be assigned

For: Non-Peptide GLP-1 Agonists

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on March 11, 2003.

Rashida Haji